Skip to main content
SpringerLink
Log in

Cyclosporin Pharmacokinetics in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Cyclosporin is an immunosuppressant used in organ transplantation and selected autoimmune diseases such as rheumatoid arthritis. In both these indications, the elderly represent an important and growing segment of the patient population. Cyclosporin is primarily eliminated via biotransformation by cytochrome P450 (CYP)3A in the gut wall and liver. Additionally, P-glycoprotein (mdr-1) located in the gastrointestinal epithelium can affect affect blood drug concentrations after oral administration of cyclosporin, presumably by counter-transporting the drug from the systemic circulation back into the gastrointestinal lumen. Theoretically, age-related alterations in either of these pathways could affect cyclosporin disposition in the elderly. These general pharmacological considerations together with the narrow therapeutic index of cyclosporin between minimally immunosuppressive concentrations and those associated with adverse events, underscore the need for dedicated pharmacokinetic studies in the elderly. Single dose studies have demonstrated that cyclosporin pharmacokinetics are not different in healthy elderly individuals compared with healthy young adults, nor is the between-subject variability in pharmacokinetic parameters more heterogenous in healthy elderly individuals. Similarly, there were no apparent differences in cyclosporin disposition in elderly patients with rheumatoid arthritis compared with healthy young and elderly individuals. Whether pharmacokinetic variability may be increased in elderly patients has not been rigorously addressed and requires investigation in a larger patient population for a definitive conclusion. A population pharmacokinetic study of cyclosporin in organ transplant patients, including elderly allograft recipients up to 75 years of age, did not identify age as a covariable influencing cyclosporin pharmacokinetics. Hence, the available pharmacokinetic data in the elderly do not reveal any major differences from the disposition characterised in younger individuals.

It is generally recognised that the elderly are more prone to drug-related adverse experiences and are at greater risk for drug-drug interactions secondary to polypharmacy. The former factor may underlie, in part, the increased incidence of renal adverse events reported in patients with rheumatoid arthritis over 65 years of age receiving cyclosporin. Clinical experience with cyclosporin in elderly organ transplant recipients has not revealed a tolerability profile remarkably different from those in younger patients. Polypharmacy may have specific relevance for elderly patients treated with cyclosporin since this agent is a substrate of both CYP3A and P-glycoprotein, both of which are important in the elimination of many commonly used drugs. This implies that the clinician prescribing cyclosporin for an elderly patient must exercise a heightened awareness for potential drug-drug interactions which could affect the pharmacokinetics of cyclosporin.

Based on the available cyclosporin pharmacokinetic data in adults, no age-related administration adaptations appear necessary for its use in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472–95

    Article  PubMed  CAS  Google Scholar 

  2. Wells G, Tugwell P. International consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 32: 1–3

    Article  Google Scholar 

  3. Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management. Drugs Aging 1998; 3: 487–501

    Article  Google Scholar 

  4. Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland. Clin Exp Rheumatol 1996; 14: 537–42

    PubMed  CAS  Google Scholar 

  5. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997; 33: 302–31

    Article  PubMed  CAS  Google Scholar 

  6. Dawling S, Crome P. Clinical pharmacokinetics in the elderly: an update. Clin Pharmacokinet 1989; 17: 236–63

    Article  PubMed  CAS  Google Scholar 

  7. Kaminsky LS, Fasco MJ. Small intestine cytochrome P450. Crit Rev Toxicol 1992; 21: 407–22

    Article  CAS  Google Scholar 

  8. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492–7

    Article  PubMed  CAS  Google Scholar 

  9. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–90

    Article  PubMed  CAS  Google Scholar 

  10. Webber IR, Peters WHM, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992; 33: 661–4

    Article  PubMed  CAS  Google Scholar 

  11. Woodhouse KM, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22–35

    PubMed  CAS  Google Scholar 

  12. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3 A. Biochem Pharmacol 1992; 44: 275–83

    Article  PubMed  CAS  Google Scholar 

  13. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single and multiple dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990; 39: 161–4

    Article  PubMed  CAS  Google Scholar 

  14. Robertson DRC, Waller DG, Renwick AG, et al. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297–305

    Article  PubMed  CAS  Google Scholar 

  15. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735–8

    Article  PubMed  CAS  Google Scholar 

  16. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–80

    PubMed  CAS  Google Scholar 

  17. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bio-availability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60

    Article  PubMed  CAS  Google Scholar 

  18. Gupta S. P-glycoprotein expression and regulation: age-related changes and potential effects on drug therapy. Drugs Aging 1995; 7: 420–37

    Article  Google Scholar 

  19. Denham MJ. Adverse drug reactions. Br Med Bull 1990; 46: 53–62

    PubMed  CAS  Google Scholar 

  20. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991; 11: 110S–8

    PubMed  CAS  Google Scholar 

  21. Bjerrum L, Sogarrd J, Hallas J, et al. Polypharmacy: correlations with sex, age and drug regimen. Eur J Clin Pharmacol 1998; 54: 197–202

    Article  PubMed  CAS  Google Scholar 

  22. Lampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159–68

    Article  PubMed  CAS  Google Scholar 

  23. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595–606

    PubMed  CAS  Google Scholar 

  24. Ball PE, Munzer H, Keller HP, et al. Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem 1988; 34: 257–60

    PubMed  CAS  Google Scholar 

  25. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1989; 16: 331–53

    Google Scholar 

  26. Food and Drug Administration Center for Drug Evaluation. Guidance: statistical procedures for bioequivalence studies. Rockville (MD): Food and Drug Administration Center for Drug Evaluation, 1992

    Google Scholar 

  27. Schuirmann DJ. A comparison of the two one-sided procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–80

    PubMed  CAS  Google Scholar 

  28. Kahan BD, Kramer WG, Wideman C. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459–67

    Article  PubMed  CAS  Google Scholar 

  29. Kyhl LEB, Rasmussen SN, Aarons L, et al. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart, and heart-lung transplanted patients [abstract]. Transplant Proc 1998; 30: 1680

    Article  PubMed  CAS  Google Scholar 

  30. Torley H, Yocum D. Effects of dose and treatment duration on adverse experiences with cyclosporine in RA: analysis of North American trials [abstract]. Arthritis Rheum 1994; 37: Suppl.: 334

    Google Scholar 

  31. Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7: 420–37

    Article  PubMed  CAS  Google Scholar 

  32. Santiago-Delphin EA. Transplantation in the elderly: changing philosophy. Transplant Proc 1996; 28: 3408–9

    Google Scholar 

  33. Mallick NP, Dyer P, Johnson RW. Transplantation in the elderly. Nephrol Dial Transplant 1996; 11Suppl. 9: 95–7

    Article  PubMed  Google Scholar 

  34. Cantarovich D, Baatard R, Baranger T, et al. Cadaveric renal transplantation after 60 years of age: a single center experience. Transplant Int 1994; 7: 33–8

    CAS  Google Scholar 

  35. Pirsch JD, Stratta RJ, Armbrust MJ, et al. Cadaveric renal transplantation with cyclosporine in patients more than 60 years of age. Transplantation 1989; 47: 259–61

    Article  PubMed  CAS  Google Scholar 

  36. Vivas CA, Hickey DP, Jordan ML, et al. Renal transplantation in patients 65 years old or older. J Urol 1992; 147: 990–3

    PubMed  CAS  Google Scholar 

  37. Smits JM, DeMeester J, Persijn GG, et al. Long-term results of solid organ transplantation: report from the Eurotransplant International Foundation. Clin Transplant 1996; 10: 109–27

    Google Scholar 

  38. Anderson IF, Helve T, Hannonen P, et al. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporin: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. J Rheumatol 1999; 26: 556–62

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Clinical Pharmacology and Drug Metabolism Pharmacokinetics, Novartis Pharma AG, Basel, Switzerland

    John M. Kovarik & E. Ulrich Koelle

Authors
  1. John M. Kovarik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Ulrich Koelle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Kovarik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovarik, J.M., Koelle, E.U. Cyclosporin Pharmacokinetics in the Elderly. Drugs Aging 15, 197–205 (1999). https://doi.org/10.2165/00002512-199915030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915030-00003

Keywords

Search

Navigation